

Chetan B Mukhtyar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7071642/chetan-b-mukhtyar-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98 papers	4,495 citations	22 h-index	67 g-index
127 ext. papers	5,893 ext. citations	3.4 avg, IF	5 L-index

#	Paper	IF	Citations
98	EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 310-7	2.4	707
97	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1583-94	2.4	628
96	Modification and validation of the Birmingham Vasculitis Activity Score (version 3). <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1827-32	2.4	555
95	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 488-94	2.4	501
94	EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 318-23	2.4	448
93	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1004-10	2.4	273
92	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 19-30	2.4	270
91	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011 , 63, 588-96	4.7	116
90	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018 , 4, e000598	5.9	85
89	Self-assessment questionnaire: SAQs and answers are ONLINE for RCP fellows and collegiate members. <i>Clinical Medicine</i> , 2013 , 13, 404-406	1.9	78
88	65. Blau syndrome treated with sequential biologics. <i>Rheumatology Advances in Practice</i> , 2018 , 2,	1.1	78
87	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019 , 10, 5120	17.4	71
86	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. <i>Rheumatology</i> , 2011 , 50, 899-905	3.9	62
85	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020 , 59, e1-e23	3.9	57
84	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Care and Research</i> , 2011 , 63, 1055-61	4.7	47
83	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 80-5	2.4	39
82	Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 4, iv31-6	2.4	29

81	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018 , 45, 1289-1295	4.1	29
80	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020 , 59, 487-494	3.9	27
79	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1357-71	4.1	26
78	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020 , 59, e24-e32	3.9	25
77	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017 , 44, 1515-1521	4.1	24
76	Cardiovascular involvement in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 419-28	5.3	21
75	Rituximab in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2017 , 19, 6	4.9	19
74	Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. <i>Autoimmunity Reviews</i> , 2019 , 18, 535-541	13.6	18
73	Standardized grip strength as an outcome measure in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013 , 42, 289-93	1.9	17
72	Outpatient assessment of systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 713-32	5.3	17
71	The role of biologic therapies in the management of systemic vasculitis. <i>Autoimmunity Reviews</i> , 2006 , 5, 273-8	13.6	17
70	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017 , 3, e000449	5.9	16
69	Revising DAS28 scores for remission in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2014 , 33, 269-72	3.9	15
68	Isolated large vessel pulmonary vasculitis as a cause of chronic obstruction of the pulmonary arteries. <i>Pulmonary Circulation</i> , 2011 , 1, 425-9	2.7	14
67	Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2019 , 58, 889-896	3.9	12
66	Long-term damage to the ENT system in Wegener's granulomatosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2011 , 268, 733-9	3.5	11
65	Refractory urticarial vasculitis responsive to anti-B-cell therapy. <i>British Journal of Dermatology</i> , 2009 , 160, 470-2	4	11
64	Primary obturator pyomyositis. <i>British Journal of Rheumatology</i> , 2005 , 44, 408-10		10

63	Refractory Wegener's meningitis treated with rituximab. <i>Journal of Rheumatology</i> , 2007 , 34, 900-1	4.1	10
62	Validating a diagnostic GCA ultrasonography service against temporal artery biopsy and long-term clinical outcomes. <i>Clinical Rheumatology</i> , 2020 , 39, 1325-1329	3.9	9
61	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021 , 60, 617-628	3.9	8
60	Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen. <i>Rheumatology Advances in Practice</i> , 2019 , 3, rkz001	1.1	7
59	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 94-111	5.3	6
58	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
57	SP0095 EULAR/ERA-EDTA Recommendations for The Management of ANCA-Associated Vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 24.1-24	2.4	6
56	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020 , 47, 1379-1384	4.1	4
55	Ultrasonography in the diagnosis and follow-up of giant cell arteritis. <i>Rheumatology</i> , 2021 , 60, 2528-2536	3.9	4
54	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. <i>Rheumatology</i> , 2020 , 59, 727-731	3.9	3
53	How to treat ANCA-associated vasculitis: practical messages from 2016 EULAR/ERA-EDTA recommendations. <i>Polish Archives of Internal Medicine</i> , 2016 , 126, 781-788	1.9	3
52	Carcinomatous polyarthrititis as a presenting manifestation of papillary carcinoma of thyroid gland. <i>Indian Journal of Rheumatology</i> , 2016 , 11, 42	0.5	3
51	Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. <i>Lupus Science and Medicine</i> , 2019 , 6, e000337	4.6	3
50	OMERACT definition and reliability assessment of chronic ultrasound lesions of the axillary artery in giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 951-956	5.3	3
49	The relationship between glycated haemoglobin levels and the risk of giant cell arteritis - a case-control study. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa018	1.1	2
48	Pregnancy and systemic vasculitis. <i>Indian Journal of Rheumatology</i> , 2016 , 11, 145	0.5	2
47	Erdheim-Chester Disease: Two cases from an ophthalmic perspective. <i>American Journal of Ophthalmology Case Reports</i> , 2020 , 20, 100984	1.3	2
46	OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 74.2-74	2.4	2

45	Cutaneous Vasculitis 2016 , 1-43		1
44	Response to: 'Renal biopsies should be performed whenever treatment strategies depend on renal involvement' by Chemouny. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e28	2.4	1
43	Eosinophilic Granulomatosis with Polyangiitis [EGPA (Churg-Strauss Syndrome) 2015 , 79-90		1
42	Editorial [Hot Topic: Clinical Trials in ANCA Associated Vasculitis (Guest Editor: Chetan Mukhtyar)]. <i>Current Immunology Reviews</i> , 2011 , 7, 385-387	1.3	1
41	Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 569-70	2.4	1
40	Primary Angiitis of the Central Nervous System Vasculitis 2015 , 185-190		1
39	Improving the quality of care for people with giant cell arteritis. <i>Clinical Medicine</i> , 2021 , 21, e371-e374	1.9	1
38	Are PR3 positive and MPO positive GPA the same disease?. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22 Suppl 1, 86-89	2.3	1
37	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1139-1145	5.3	1
36	Comment on: An unusual cause of a halo sign.. <i>Rheumatology</i> , 2022 ,	3.9	1
35	Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist.. <i>Rheumatology</i> , 2022 ,	3.9	1
34	Secondary Vasculitis 2015 , 173-184		0
33	AB1178 AN AUDIT OF ORIGINATOR ADALIMUMAB TO BIOSIMILAR SWITCH IN TWO HOSPITALS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1880.2-1880	2.4	0
32	Testicular vasculitis: a diagnostic conundrum. <i>Oxford Medical Case Reports</i> , 2020 , 2020, omaa028	0.6	0
31	FRI0518 Ultrasound Definitions for Vasculitis in Cranial and Large Vessel Giant Cell Arteritis: Results of A Delphi Survey of The Omeract Ultrasound Large Vessel Vasculitis Group. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 626.2-626	2.4	0
30	Microscopic Polyangiitis 2015 , 91-102		
29	Classification and Epidemiology 2015 , 7-13		
28	IgA Vasculitis 2015 , 127-137		

27 Cryoglobulinemic Vasculitis **2015**, 153-158

26 IgG4 Related Disease **2015**, 205-212

25 General Principles of Treatment **2015**, 25-36

24 Behçet Disease **2015**, 139-152

23 Vasculitis Mimics **2015**, 159-171

22 Behçet's pulmonary artery aneurysms treated with infliximab and monitored with the 6-min walk test. *Oxford Medical Case Reports*, **2016**, 2016, 94-6 0.6

21 Pattern recognition is a sequential process-accurate diagnosis and treatment 20 years after presentation. *Oxford Medical Case Reports*, **2019**, 2019, omz058 0.6

20 ANCA-associated vasculitis [Should we change the standard of care?]. *Indian Journal of Rheumatology*, **2015**, 10, S54-S58 0.5

19 P9. Giant cell arteritis--over diagnosed?. *Rheumatology*, **2014**, 53, i15-i15 3.9

18 SAT0153 Giant Cell Arteritis [Incidence and Mortality. *Annals of the Rheumatic Diseases*, **2013**, 72, A633.3-A634

17 Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis. *Current Immunology Reviews*, **2011**, 7, 429-434 1.3

16 Disseminated Mycobacterium avium infection masquerading as longstanding polymyositis. *JRSM Short Reports*, **2011**, 2, 94

15 Update on the use of biologics in primary systemic vasculitides. *Expert Review of Clinical Immunology*, **2007**, 3, 901-11 5.1

14 Pregnancy in Systemic Vasculitis **2020**, 153-162

13 THU0553 A HEALTH ECONOMIC ANALYSIS OF THE USE OF COLOUR DOPPLER ULTRASONOGRAPHY AS THE PRIMARY DIAGNOSTIC MODALITY IN PATIENTS WITH SUSPECTED GIANT CELL ARTERITIS. *Annals of the Rheumatic Diseases*, **2020**, 79, 517.2-517 2.4

12 General Presentation of the Vasculitides **2015**, 15-23

11 Takayasu Arteritis **2015**, 53-62

10 Polyarteritis Nodosa **2015**, 103-115

9 Cogan's Syndrome **2015**, 199-203

8 Comment on: The nose is an organ too: reply. *Rheumatology*, **2020**, 59, e114 3.9

7 The long-term use of tocilizumab in giant cell arteritis. *Rheumatology*, **2021**, 60, 4447-4449 3.9

6 Giant cell arteritis. *British Dental Journal*, **2021**, 230, 687 1.2

5 Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et al. *Clinical Microbiology and Infection*, **2019**, 25, 531-532 9.5

4 Patient perceptions of co-morbidities in inflammatory arthritis. *Rheumatology Advances in Practice*, **2021**, 5, rkaa076 1.1

3 Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. *Rheumatology Advances in Practice*, **2021**, 5, rkab011 1.1

2 Response to: Correspondence on 'Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis' by Scheicht.. *Annals of the Rheumatic Diseases*, **2022**, 2.4

1 Maxillary artery involvement in giant cell arteritis demonstrated by ultrasonography. *Journal of the Royal College of Physicians of Edinburgh, The*, **2021**, 51, 366-368 0.9